Contributors: Swiss HIV Cohort Study; Abela, I.A.; Aebi-Popp, K.; Anagnostopoulos, A.; Battegay, M.; Bernasconi, E.; Braun, D.L.; Bucher, H.; Calmy, A.; Cavassini, M.; Ciuffi, A.; Dollenmaier, G.; Egger, M.; Elzi, L.; Fehr, J.; Fellay, J.; Furrer, H.; Fux, C.; Günthard, H.F.; Hachfeld, A.; Haerry, D.; Hasse, B.; Hirsch, H.; Hoffmann, M.; Hösli, I.; Huber, M.; Jackson-Perry, D.; Kahlert, C.; Kaiser, L.; Keiser, O.; Klimkait, T.; Kouyos, R.D.; Kovari, H.; Kusejko, K.; Labhardt, N.; Leuzinger, K.; Martinez de Tejada, B.; Marzolini, C.; Metzner, K.J.; Müller, N.; Nemeth, J.; Nicca, D.; Notter, J.; Paioni, P.; Pantaleo, G.; Perreau, M.; Rauch, A.; Salazar-Vizcaya, L.; Schmid, P.; Speck, R.; Stöckle, M.; Tarr, P.; Trkola, A.; Wandeler, G.; Weisser, M.; Yerly, S.
نبذة مختصرة : Autoantibodies neutralizing type I interferons (IFN-Is) can underlie infection severity. Here, we trace the development of these autoantibodies at high-resolution using longitudinal samples from 1,876 well-treated individuals living with HIV over a 35-year period. Similar to general populations, ∼1.9% of individuals acquired anti-IFN-I autoantibodies as they aged (median onset ∼63 years). Once detected, anti-IFN-I autoantibodies persisted lifelong, and titers increased over decades. Individuals developed distinct neutralizing and non-neutralizing autoantibody repertoires at discrete times that selectively targeted combinations of IFNα, IFNβ, and IFNω. Emergence of neutralizing anti-IFNα autoantibodies correlated with reduced baseline IFN-stimulated gene levels and was associated with subsequent susceptibility to severe COVID-19 several years later. Retrospective measurements revealed enrichment of pre-existing autoreactivity against other autoantigens in individuals who later developed anti-IFN-I autoantibodies, and there was evidence for prior viral infections or increased IFN at the time of anti-IFN-I autoantibody triggering. These analyses suggest that age-related loss of self-tolerance prior to IFN-I immune-triggering poses a risk of developing lifelong functional IFN-I deficiency.
No Comments.